VHL inactivation in renal cell carcinoma: Implications for diagnosis, prognosis and treatment

Expert Review of Anticancer Therapy

Volumn 8, Issue 1, 2008, Pages 63-73

  Rathmell, W Kimryn ^a   Chen, Shufen ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Angiogenesis; HIF; Renal cell carcinoma; VEGF; von Hippel Lindau

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CARBONATE DEHYDRATASE IX; CARBONATE DEHYDRATASE IX ANTIBODY; CHEMOKINE RECEPTOR CXCR4; CHETOMIN; CHROMOMYCIN A3; ENZYME ANTIBODY; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INTERFERON; PLACEBO; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; RECOMBINANT ALPHA2B INTERFERON; SORAFENIB; STROMAL CELL DERIVED FACTOR 1; SUNITINIB; TEMSIROLIMUS; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN; VHL PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; CLEAR CELL CARCINOMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE REGIMEN; DRUG SYNTHESIS; GENE CONTROL; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; METASTASIS; MOLECULAR BIOLOGY; MONOTHERAPY; NEPHRECTOMY; NONHUMAN; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN STABILITY; PROTEIN TARGETING; REVIEW; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; KIDNEY TUMOR; METABOLISM;

CARCINOMA, RENAL CELL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 38349035880     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.1.63     Document Type: Review

References (93)

1. Aiello LP, George DJ, Cahill MT et al. Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology 109(9), 1745-1751 (2002).
2. Seizinger BR, Rouleau GA, Ozelius LJ et al. von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332(6161), 268-269 (1988).
3. Los M, Jansen GH, Kaelin WG et al. Expression pattern of the von Hippel-Lindau protein in human tissues. Lab. Invest. 75(2), 231-238 (1996).
4. Latif F, Tory K, Gnarra J et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260(5112), 1317-1320 (1993).
5. Vortmeyer AC, Yuan Q, Lee YS, Zhuang Z, Oldfield EH. Developmental effects of von Hippel-Lindau gene deficiency. Ann. Neurol. 55(5), 721-728 (2004).
6. Vortmeyer AO, Huang SC, Pack SD et al. Somatic point mutation of the wild-type allele detected in tumors of patients with VHL germline deletion. Oncogene 21(8), 1167-1170 (2002).
7. Kamura T, Koepp DM, Conrad MN et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284(5414), 657-661 (1999).
8. Clifford SC, Astuti D, Hooper L et al. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1α in renal cell carcinoma. Oncogene 20(36), 5067-5074 (2001).
9. Iwai K, Yamanaka K, Kamura T et al. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc. Natl Acad. Sci. USA 96(22), 12436-12441 (1999).
10. Iliopoulos O, Kibel A, Gray S, Kaelin WG Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1(8), 822-826 (1995).
11. Blankenship C, Naglich JG, Whaley JM, Seizinger B, Kley N. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene 18(8), 1529-1535 (1999).
12. Gao J, Naglich JG, Laidlaw J et al. Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumor suppressor gene: implications for the potential organization of the human von Hippel-Lindau disease gene. Cancer Res. 55 (4), 743-747 (1995).
13. Richards FM, Schofield PN, Fleming S, Maher ER. Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum. Mol. Genet. 5(5), 639-644 (1996).
14. Knauth K, Bex C, Jemth P, Buchberger A. Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1α interactions. Oncogene 25(3), 370-377 (2006).
15. Ohh M, Takagi Y, Aso T et al. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. J. Clin. Invest. 104(11), 1583-1591 (1999).
16. Okuda H, Hirai S, Takaki Y et al. Direct interaction of the β-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. Biochem. Biophys. Res. Commun. 263(2), 491-497 (1999).
17. Ohh M, Park CW, Ivan M et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2(7), 423-427 (2000).
18. Datta K, Sundberg C, Karumanchi SA, Mukhopadhyay D. The 104-123 amino acid sequence of the β-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. Cancer Res. 61(5), 1768-1775 (2001).
19. Stickle NH, Chung J, Klco JM et al. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol. Cell Biol. 24(8), 3251-3261 (2004).
20. Sufan RI, Ohh M. Role of the NEDD8 modification of Cul2 in the sequential activation of ECV complex. Neoplasia 8(11), 956-963 (2006).
21. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG Jr. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 269(5229), 1444-1446 (1995).
22. Maxwell PH, Wiesener MS, Chang GW et al. The turnout suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399(6733), 271-275 (1999).
23. 2 sensing. Science 292(5516), 464-468 (2001).
24. Yu F, White SB, Zhao Q, Lee FS. HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl Acad. Sci. USA 98(17), 9630-9635 (2001).
25. 2-regulated prolyl hydroxylation. Science 292(5516), 468-472 (2001).
26. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294(5545), 1337-1340 (2001).
27. Jain S, Maltepe E, Lu MM, Simon C, Bradfield CA. Expression of ARNT, ARNT2, HIF α, HIF2 α and Ah receptor mRNAs in the developing mouse. Mech. Dev. 73(1), 117-123 (1998).
28. Raval RR, Lau KW, Tran MG et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell Biol. 25(13), 5675-5686 (2005).
29. Maynard MA, Ohh M. The role of hypoxia-inducible factors in cancer. Cell Mol. Life Sci. 64(16), 2170-2180 (2007).
30. Covello KL, Simon MC. HIFs, hypoxia, and vascular development. Curr. Top. Dev. Biol. 62, 37-54 (2004).
31. Kim WY, Kaelin WC, Jr. Molecular pathways in renal cell carcinoma - rationale for targeted treatment. Semin. Oncol. 33(5), 588-595 (2006).
32. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential role of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol. Cell Biol. 23(24), 9361 9374 (2003).
33. Yamakawa M, Liu LX, Belanger AJ et al. Expression of angiopoietins in renal epithelial and clear cell carcinoma cells: regulation by hypoxia and participation in angiogenesis. Am. J. Physiol. Renal Physiol. 287(4), F649-F657(2004).
34. Igarashi H, Esumi M, Ishida H, Okada K. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer 95(1), 47-53 (2002).
35. Seagroves TN, Ryan HE, Lu H et al. Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol. Cell Biol 21 (10), 3436-3444 (2001).
36. Firth JD, Ebert BL, Ratcfiffe PJ. Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J. Biol. Chem. 270(36), 21021-21027 (1995).
37. Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1α-dependent mechanism. J. Biol. Chem. 281(14), 9030-9037 (2006).
38. Leo C, Giaccia AJ, Denko NC. The hypoxic tumor microenvironment and gene expression. Semin.Radiat. Oncol. 14(3), 207-214 (2004).
39. Rathmell WK, Hickey MM, Bezman NA et al. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Cancer Res. 64(23), 8595-8603 (2004).
40. Li L, Zhang L, Zhang X et al. Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol. Cell Biol. 27(15), 5381-5392 (2007).
41. Ang SO, Chen J, Hirota K et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat. Genet 32(4), 614-621 (2002).
42. Pastore YD, Jelinek J, Ang S et al. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 101(4), 1591-1595 (2003).
43. Ang SO, Chen H, Gordeuk VR et al. Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells Mol. Dis. 28(1), 57-62 (2002).
44. Pastore Y, Jedlickova K, Guan Y et al. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycyrhemia. Am. J. Hum. Genet. 73(2), 412-419 (2003).
45. Gordenk VR, Sergueeva AI, Miasnikova GY et al. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 103(10), 3924-3932 (2004).
46. Hickey MM, Lam JC, Bezman NA, Rathmell WK, Simon MC. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2α signaling and splenic erythrocycosis. J. Clin. Invest. 117(12), 3879-3889 (2007).
47. Kasuno K, Takabuchi S, Fukuda K et al. Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J. Biol. Chem. 279(4), 2550-2558 (2004).
48. Okuda H, Saitoh K, Hirai S et al. The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J. Biol. Chem. 276(47), 43611-43617 (2001).
49. Lee S, Nakamura E, Yang H et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8(2), 155-167 (2005).
50. Kuehn EW, Walz G, Benzing T. von Hippel Lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development. Cancer Res. 67(10), 4537-1540 (2007).
51. Lolkema MP, Mans DA, Ulfman LH et al. Allele-specific regulation of primary cilia function by the von Hippel-Lindau tumor suppressor. Eur. J. Hum. Genet. (2007) (Epub ahead of print).
52. Esteban MA, Harten SK, Tran MG, Maxwell PH. Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein. J. Am. Soc. Nephrol. 17(7), 1801-1806 (2006).
53. Lutz MS, Burk RD. Primary cilium formation requires von Hippel-Lindau gene function in renal-derived cells. Cancer Res. 66(14), 6903-6907 (2006).
54. Kurban G, Hudon V, Duplan E, Ohh M, Pause A. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angtogenesis. Cancer Res. 66(3), 1313-1319 (2006).
55. Calzada MJ, Esteban MA, Feijoo-Cuaresma M et al von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms. Cancer Res. 66(3), 1553-1560 (2006).
56. Grosfeld A, Stolze IP, Cockman ME et al. Interaction of hydroxylated collagen IV with the von Hippel-Lindau tumor suppressor. J. Biol. Chem. 282(18), 13264-13269 (2007).
57. Kurban G, Duplan E, Randal N et al. Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated. collagen IV α. 2. Oncogene (2007) (Epub ahead of print).
58. Ohh M, Yauch RL, Lonergan KM et al. The von Hippel Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1(7), 959-968 (1998).
59. Hoffman MA, Ohh M, Yang H et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 10(10), 1019-1027 (2001).
60. Hughes MD, Kapllani E, Alexander AE, Burk RD, Schoenfeld AR. HIF-2α downregulation in the absence of functional VHL is not sufficient for renal cell differentiation. Cancer Cell Int. 7, 13 (2007).
61. Kamada M, Suzuki K, Kato Y, Okuda H, Shuin T. von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility. Cancer Res. 61(10), 4184-4189 (2001).
62. Yao M, Tabuchi H, Nagashima Y et al. Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J. Pathol. 205(3), 377-387 (2005).
63. Lani JS, Belldegrun AS, Figlin RA. Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy. Clin. Cancer Res. 10(18 Pt 2), S6304-S6309 (2004).
64. Kim HL, Seligson D, Liu X et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin. Cancer Res. 10(16), 5464-5471 (2004).
65. Wykoff CC, Beasley NJ, Wasson PH et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 60(24), 7075-7083 (2000).
66. Grabmaier K, A de Weijert MC, Verhaegh GW, Schalken JA, Oosterwijk E. Strict regulation of CAIX(G250/MN) by HIF-1α in clear cell renal cell carcinoma. Oncogene 23(33), 5624-5631 (2004).
67. Leibovich BC, Sheinin Y, Lohse CM et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J. Clin. Oncol. 25(30), 4757-4764 (2007).
68. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. 11(10), 3714-3721 (2005).
69. Opavsky R, Pastorekova S, Zelnik V et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 33(3), 480-487 (1996).
70. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal dear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9(2), 802-811 (2003).
71. Pantuck AJ, Fang Z, Liu X et al. Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. (2007) (Abstract 4535).
72. Pan J, Mestas J, Burdick MD et al. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol. Cancer 5, 56 (2006).
73. Staler P, Sulitkova J, Lisztwan J et al. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425(6955), 307-311 (2003).
74. Zagzag D, Krishnamachary B, Yee H et al. Stromal cell-derived factor-1α and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res. 65(14), 6178-6188 (2005).
75. Yao M, Yoshida M, Kishicla T et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J. Natl Canter Inst. 94(20), 1569-1575 (2002).
76. Kim JH, Jung CW, Cho YH et al. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol. Rep. 13(5), 859-864 (2005).
77. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349(5), 427-434 (2003).
78. Escudier B, Koralewski P, Pluzanska A et al. A randomized, controlled, double-blind Phase III study (AVOREN) of bevacizumab/ interferon-α2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. (2007) (Abstract 3).
79. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. Cancer and Leukemia Group B 90206: a randomized Phase III trial of interferon-α or interferon-α plus antivascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin. Cancer Res. 10(8), 2584-2586 (2004).
80. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24(16), 2505-2512 (2006).
81. Fscudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007).
82. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007).
83. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24(1), 16-24 (2006).
84. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007).
85. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat. Rev. Drug Discov. 2(10), 803-811 (2003).
86. Mabjeesh NJ, Post DE, Willard MT et al. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res. 62(9), 2478-2482 (2002).
87. Isaacs JS, Jung YJ, Mimnaugh EG et al. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 α-degradadve pathway. J. Biol. Chem. 277(33), 29936-29944 (2002).
88. Kung AL, Zabludoff SD, France DS et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6(1), 33-43 (2004).
89. Sutphin PD, Chan DA, Li JM et al. Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells. Cancer Res. 67(12), 5896-5905 (2007).
90. Davis ID, Liu Z, Saunders W et al. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Cancer Immun. 7, 14 (2007).
91. Davis ID, Wiseman GA, Lee FT et al. A Phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun. 7, 13 (2007).
92. Rini BI, Jaeger E, Weinberg V et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and von Hippel-Lindau gene status. Br. J. Urol. Int. 98(4), 756-762 (2006).
93. Choueiri TK, Vaziri SA, Rini BI et al. Use of von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) targeted therapy in metastatic renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 25(18S) (2007) (Abstract 5012).